Since their introduction into clinical oncology, immune checkpoint inhibitors (ICIs), specifically programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) inhibitors, have led to significant breakthroughs in the management of lung cancer and are notably enhancing patient survival [2]. This evidence concerns the gene CD274 and lung carcinoma.